Boehringer Ingelheim Animal Health

Boehringer Ingelheim Animal Health is the animal-health business of Boehringer Ingelheim, a privately held pharmaceutical group headquartered in Ingelheim am Rhein, Germany. The business serves two broad areas: companion-animal health, including care for pets such as dogs and cats, and production-animal health, including livestock. Its portfolio spans veterinary medicines and vaccines, with products intended for prevention and treatment of animal diseases and for supporting animal health across these markets. The current business took shape in 2017, when Boehringer Ingelheim integrated Merial, Sanofi’s animal-health business, following a wider asset exchange between the pharmaceutical companies. That combination added established veterinary products and research capabilities to Boehringer Ingelheim’s existing animal-health activities. The business operates internationally as part of the wider group rather than as an independently listed company. Boehringer Ingelheim Animal Health is positioned as a research-oriented veterinary-health provider serving both pet owners and the livestock sector through veterinary professionals, distributors, and other market channels. Its animal-health identity is distinct from the parent group’s human-pharmaceutical business, while sharing the group’s corporate ownership and broad research-led orientation. Exact current product availability and brand portfolios can vary by country.

Boehringer Ingelheim Animal Health is the animal-health business within the German pharmaceutical group Boehringer Ingelheim. The parent company has a long history in pharmaceuticals and is privately held. Its animal-health activities form a distinct business alongside its human-pharmaceutical operations, with offerings for both companion animals and livestock. A major turning point for the present-day business came in 2017. Boehringer Ingelheim and Sanofi completed an asset exchange under which Boehringer Ingelheim acquired Sanofi’s animal-health business, Merial, while Sanofi acquired Boehringer Ingelheim’s consumer-health business. Boehringer Ingelheim then combined Merial with its existing animal-health activities. The integration broadened the company’s veterinary portfolio and brought together established product lines and capabilities in animal health. The business has since operated as part of the privately held Boehringer Ingelheim group, rather than as a separately listed company. Its activities cover veterinary medicines and vaccines for pets and production animals, with products and availability varying across markets. The business’s public-facing identity reflects this combined animal-health operation; it should not be confused with the parent company’s human-medicine business or with Merial as a separately owned business before the 2017 transaction.

• 2017

  Merial integration

Research-oriented animal-health provider serving companion-animal and livestock markets with veterinary medicines and vaccines.

• NexGard

  A companion-animal parasite-control brand in Boehringer Ingelheim Animal Health’s portfolio.

• Frontline

  An established animal-health brand associated with parasite control for pets.

• Heartgard

  A companion-animal preventive-health brand.

• Purevax

  A veterinary vaccine brand for cats.

• Bovilis

  A vaccine brand for cattle.

• 2017

  Asset exchange with SanofiOther

1. 1Boehringer Ingelheim official websiteboehringer-ingelheim.com